HOUSTON, March 16, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, today announced the
closing of an underwritten public offering of 32,282,857 shares of
its common stock at a public offering price of $1.75 per share. The gross proceeds to
Marker from the offering, before deducting the underwriting
discounts and commissions and other estimated offering expenses,
are expected to be approximately $56.5 million.
Piper Sandler & Co. acted as
the sole active book-running manager for the offering. Cantor
Fitzgerald & Co. also acted as a book-running manager for the
offering. Oppenheimer & Co. Inc. acted as the lead manager and
Roth Capital Partners acted as the co-manager for the offering.
The offering was made pursuant to a shelf registration
statement, including a base prospectus, filed by Marker that was
declared effective by the Securities and Exchange Commission
("SEC") on June 25, 2019. The
offering was made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. An electronic copy of the final prospectus supplement
and accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC's website at www.sec.gov.
Alternatively, a copy of the final prospectus supplement and the
accompanying prospectus relating to the offering may be obtained by
contacting Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, by
telephone at (800) 747-3924 or by email at prospectus@psc.com; or
Cantor Fitzgerald & Co., Attention: Capital Markets Department,
499 Park Avenue, New York, NY
10022, or email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
View original
content:http://www.prnewswire.com/news-releases/marker-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-301248826.html
SOURCE Marker Therapeutics, Inc.